Search results for "Tissue specimen"

showing 1 items of 1 documents

Reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple negative brea…

2019

Abstract Background Atezolizumab (an anti–PD-L1 antibody) has shown clinical activity alone or in combination with nab-paclitaxel in patients (pts) with first-line metastatic TNBC who have PD-L1 expression on their tumour-infiltrating immune cells (IC). We analysed the performance of 4 PD-L1 IHC assays for PD-L1 IC expression in TNBC. Methods Thirty archival TNBC tissue specimens were selected from a set of 107 based on PD-L1 IC expression per VENTANA SP142 ( 5%: 8 cases), to represent the distribution of PD-L1 IC–positivity in the pivotal atezolizumab studies (Emens et al., SABCS 2018; JAMA Oncol 2019). Serial histologic sections were stained with VENTANA SP142 and SP263, and DAKO 22C3 and…

0301 basic medicinemedicine.medical_specialtybusiness.industryConcordanceStock optionsHematologyIc testing03 medical and health sciences030104 developmental biology0302 clinical medicineTissue specimenOncologyPaclitaxel protein-bound030220 oncology & carcinogenesisFamily medicineComparison studyMedicineIn patientbusinessProgrammed deathAnnals of Oncology
researchProduct